The company stood its ground with 'final offer' on key therapy

April 4, 2022 Latest News BioPharma News of the Day

This is a preview of subscriber content

Subscribe now to continue reading.

The PBAC considered the therapy at least four times with the Public Summary Document confirming it effectively relented in response to the company standing its ground on key aspects of the listing. …

Subscribe now to continue reading.

Latest Video

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation
April 28, 2026 - Latest News
Quarter of a century after the case that led to the PBAC's unaccountability loop
April 28, 2026 - Latest News
Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics
April 28, 2026 - Latest News
This makes it twice in two weeks, so at what point do we accept there's a problem?
April 28, 2026 - Latest News
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - Latest News

The company stood its ground with 'final offer' on key therapy

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access

Sign In

The company stood its ground with 'final offer' on key therapy

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

Follow Us

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access